Highlighting the 2020-2021 ACS Division of Medicinal Chemistry Award Winners.
Highlighting the 2020-2021 ACS Division of Medicinal Chemistry Award Winners.
复制标题
重点介绍 2020-2021 年 ACS 药物化学部获奖者。
DOI：
10.1021/acs.jmedchem.2c00975
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
J. Schwarz
中科院分区：
文献类型：
--
作者：
Lori Ferrins;J. Schwarz
药物化学部门奖向任何科学家或科学家团队开放，他们的研究直接或间接地对药物化学产生了重大影响。2022年的奖项授予劳伦斯·哈曼博士，以表彰他的科学贡献。哈曼博士是风险投资支持的生物技术初创公司Interdict Bio的联合创始人、总裁兼首席执行官。到目前为止，Hamann博士的工作已经导致了16种研究新药，其中包括几种一流的治疗方法，以及两种已推出的药物：治疗2型糖尿病的DPP4抑制剂saxagliptin(Onlyza)和第一种治疗丙型肝炎的NS5A抑制剂Daclatasvir(Daklinza)。Hamann博士还因其在该领域的领导地位而受到认可，他一贯推动创新，并促进与学术界的合作，以开发新颖的合成方法和新的疗法。《药物化学杂志》最近的一篇社论宣布了菲利普·S·波托盖斯药物化学杂志-药物化学分部讲座的获奖者是玛格丽特·朱-莫耶博士和丹尼尔·帕拉西奥斯博士。Chu-Moyer博士被授予著名研究员的讲师职位。Chu-Moyer博士是安进公司负责研究的副总裁和小分子治疗发现部门的负责人。这一奖项是为了表彰Chu-Moyer博士为发现Sotorasib所做的贡献，Sotorasib是一种一流的KRAS-G12C抑制剂，是该团队的领导者，也是其快速开发和进入临床的倡导者。帕拉西奥斯博士被授予年轻研究员奖，这是该奖项的一个新类别，旨在表彰在过去10年内完成终极学位的科学家。帕拉西奥斯博士是诺华生物医学研究所的高级首席科学家。在诺华任职期间，帕拉西奥斯博士已经在几个治疗领域产生了重大影响，并因其突破化学和生物学界限的能力而受到认可。他曾在多个项目中担任化学领导，包括神经科学组合中的一个项目，该项目导致了精神障碍的临床候选人的交付。爱德华·E·斯米斯曼奖授予一位后期科学家，他的研究、教学或服务对药物化学领域的智力和理论发展产生了重大影响。2021年的奖项授予斯克里普斯研究中心的杰弗里·凯利教授。凯利教授使用一种面向化学的方法来了解转甲状腺激素聚集的机制，然后在此基础上开发出一种小分子治疗策略。这项工作的最终结果是通过催化两个使用不同小分子抑制剂的安慰剂对照的人类临床试验，在转甲状腺素淀粉样病的背景下对淀粉样蛋白假说进行了药理学验证。这最终导致了他法米迪的批准，它显著减少了人类淀粉样疾病中的神经退行性变。大卫·W·罗伯逊奖表彰了阿曼达·加纳博士在药物化学领域的贡献。加纳博士是密歇根大学药物化学系的副教授。加纳博士的研究重点是解决“无法下药的”microRNA和rna−蛋白质和蛋白质−蛋白质之间的相互作用。她最早的突破之一是发展了高通量筛选试验，从而识别出小分子抑制微RNA、−蛋白质和蛋白质−蛋白质相互作用的物质。加纳博士同时正在探索eif4E抑制剂的合理设计，eif4E是肿瘤学中的一个高兴趣靶点；她开发了基于多肽的蛋白质−蛋白质相互作用抑制剂以及…
The Division of Medicinal Chemistry award is open to any scientist, or a team of scientists, whose research has, directly or indirectly, had a significant effect on medicinal chemistry. The 2022 award is given to Dr. Lawrence Hamann in recognition of his scientific contributions. Dr. Hamann is Co-founder, President, and CEO of Interdict Bio, a venture-backed biotech startup. To date, Dr. Hamann’s work has led to> 16 Investigational New Drugs, including several first-in-class therapeutics, and two launched drugs: saxagliptin (Onglyza), a DPP4 inhibitor for type 2 diabetes, and daclatasvir (Daklinza), the first NS5A inhibitor which is part of a curative combination for hepatitis C. Dr. Hamann is also recognized for his leadership in the field, having consistently driven innovation, and fostering collaborations with academia to develop novel synthetic methods and new therapeutics. A recent editorial in the Journal of Medicinal Chemistry announced the winners of The Philip S. Portoghese Journal of Medicinal Chemistry-Division of Medicinal Chemistry Lectureship as Dr. Margaret Chu-Moyer and Dr. Daniel Palacios. 1 Dr. Chu-Moyer is awarded the lectureship for an established investigator. Dr. Chu-Moyer is the Vice-President, Research, and head of Small Molecule Therapeutic Discovery at Amgen. This award is given in recognition of Dr. Chu-Moyer’s contributions to the discovery of sotorasib, a first-inclass KRAS-G12C inhibitor, as a leader of the team and champion of its rapid development and progression into the clinic. Dr. Palacios is awarded the young investigator award, a new category for this award which recognizes scientists who completed their terminal degree within the past 10 years. 2 Dr. Palacios is a Senior Principal Scientist at the Novartis Institutes for BioMedical Research. Dr. Palacios has already made significant impacts in several therapeutic areas while at Novartis and is recognized for his ability to push the boundaries of chemistry and biology. He has served as a chemistry lead on multiple projects, including one within the neuroscience portfolio which led to delivery of a clinical candidate for psychiatric disorders. The Edward E. Smissman award is given to a late-stage scientist whose research, teaching, or service has had a substantial impact on the intellectual and theoretical development of the field of medicinal chemistry. The 2021 award goes to Prof. Jeffery Kelly from Scripps Research. Prof. Kelly used a chemistry-oriented approach to understand the mechanism of transthyretin aggregation and then built upon that to develop a small-molecule therapeutic strategy. This work culminated in pharmacological validation of the amyloid hypothesis in the context of transthyretin amyloid diseases by catalyzing two placebo-controlled human clinical trials with distinct smallmolecule inhibitors. This ultimately led to the approval of tafamidis, which significantly decreases neurodegeneration in human amyloid disease.The David W. Robertson award recognizes the contributions of Dr. Amanda Garner to the field of medicinal chemistry. Dr. Garner is an Associate Professor in the Department of Medicinal Chemistry at the University of Michigan. Dr. Garner’s research is focused on tackling “undruggable” microRNAs and RNA− protein and protein− protein interactions. One of her earliest breakthroughs was the development of high-throughput screening assays leading to the identification of small-molecule inhibitors of microRNA− protein and protein− protein interactions. Dr. Garner is concurrently exploring rational design of inhibitors of eIF4E, a high-interest target in oncology; she has developed peptidebased protein− protein interaction inhibitors as well as …